BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boyne DJ, Cuthbert CA, O'Sullivan DE, Sajobi TT, Hilsden RJ, Friedenreich CM, Cheung WY, Brenner DR. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open 2019;2:e194154. [PMID: 31099875 DOI: 10.1001/jamanetworkopen.2019.4154] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Petrelli F, Rulli E, Labianca R, Lonardi S, Rosati G, Dotti K, Ronzoni M, Pella N, Pusceddu V, Banzi M, Zampino MG, Yasmina M, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Sobrero A; TOSCA Investigators. Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial. Ann Oncol 2021;32:66-76. [PMID: 33098997 DOI: 10.1016/j.annonc.2020.10.477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Chen S, Li X, Zhang J, Li L, Wang X, Zhu Y, Guo L, Wang J. Six mutator-derived lncRNA signature of genome instability for predicting the clinical outcome of colon cancer. J Gastrointest Oncol 2021;12:2157-71. [PMID: 34790382 DOI: 10.21037/jgo-21-494] [Reference Citation Analysis]
3 Bonhof CS, van de Poll-Franse LV, Wasowicz DK, Beerepoot LV, Vreugdenhil G, Mols F. The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients. J Cancer Surviv 2021;15:190-200. [PMID: 33185839 DOI: 10.1007/s11764-020-00923-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
4 Wang X, Frohlich MM, Chu E. Suboptimal Completion Rates, Adverse Events, Costs, Resource Utilization, and Cost Impact of Noncompletion in Oral Adjuvant Capecitabine-Based Chemotherapy in Patients With Early-Stage Colon Cancer. Clin Colorectal Cancer 2021:S1533-0028(21)00035-9. [PMID: 34112610 DOI: 10.1016/j.clcc.2021.05.002] [Reference Citation Analysis]
5 Chung E, Lee HS, Cho ES, Park EJ, Baik SH, Lee KY, Kang J. Changes in Body Composition During Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer. Cancers (Basel) 2019;12:E60. [PMID: 31878325 DOI: 10.3390/cancers12010060] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chen XH, Lin ZS, Yu J. The "addition" and "subtraction" of adjuvant chemotherapy for locally advanced colorectal cancer: where to go next? Chin Med J (Engl) 2019;132:2485-8. [PMID: 31592909 DOI: 10.1097/CM9.0000000000000473] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Johnson BA, Waddimba AC, Ogola GO, Fleshman JW Jr, Preskitt JT. A systematic review and meta-analysis of surgery delays and survival in breast, lung and colon cancers: Implication for surgical triage during the COVID-19 pandemic. Am J Surg 2021;222:311-8. [PMID: 33317814 DOI: 10.1016/j.amjsurg.2020.12.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
8 Boyne DJ, Cheung WY, Hilsden RJ, Sajobi TT, Batra A, Friedenreich CM, Brenner DR. Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer. JAMA Netw Open 2021;4:e213587. [PMID: 33783516 DOI: 10.1001/jamanetworkopen.2021.3587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Boyne DJ, O'Sullivan DE, Heer EV, Hilsden RJ, Sajobi TT, Cheung WY, Brenner DR, Friedenreich CM. Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta-analysis. Cancer Med 2020;9:1613-27. [PMID: 31962372 DOI: 10.1002/cam4.2843] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Boyle JM, Kuryba A, Cowling TE, van der Meulen J, Fearnhead NS, Walker K, Braun MS, Aggarwal A. Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study. Int J Cancer 2021. [PMID: 34520572 DOI: 10.1002/ijc.33806] [Reference Citation Analysis]
11 Saeed M, Shoaib A, Kandimalla R, Javed S, Almatroudi A, Gupta R, Aqil F. Microbe-based therapies for colorectal cancer: Advantages and limitations. Semin Cancer Biol 2021:S1044-579X(21)00148-6. [PMID: 34020027 DOI: 10.1016/j.semcancer.2021.05.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Suzuki Y, Tei M, Wakasugi M, Nakahara Y, Naito A, Mikamori M, Furukawa K, Ohtsuka M, Moon JH, Imasato M, Asaoka T, Kishi K, Akamatsu H. Long-term outcomes of single-incision versus multiport laparoscopic colectomy for colon cancer: results of a propensity score-based analysis. Surg Endosc 2021. [PMID: 33638106 DOI: 10.1007/s00464-021-08367-4] [Reference Citation Analysis]